Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atacicept in Patients With IgAN
NCT07020923Phase 2Active, not recruiting
- Sponsor
- Vera Therapeutics
- Start
- May 2025
- Primary completion
- Sep 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atacicept in IgA nephropathy (IgAN) (5 arms), sponsored by Vera Therapeutics. Primary endpoint: Effect of atacicept on Gd-IgA1 at 24 weeks. Started May 2025; status: active, not recruiting.
02
Drugs
atacicept
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT07020923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07020923.